Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study.

IF 3.5 3区医学 Q2 ONCOLOGY

Frontiers in Oncology Pub Date : 2025-01-20 eCollection Date: 2024-01-01 DOI:10.3389/fonc.2024.1445558

Renxian Xie, Hongxin Huang, Qingxin Cai, Jiayang Lu, Tong Chen, Keyan Xie, Jianzhou Chen, Chuangzhen Chen

{"title":"Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study.","authors":"Renxian Xie, Hongxin Huang, Qingxin Cai, Jiayang Lu, Tong Chen, Keyan Xie, Jianzhou Chen, Chuangzhen Chen","doi":"10.3389/fonc.2024.1445558","DOIUrl":null,"url":null,"abstract":"Background: Radiotherapy can improve the survival rates of patients with glioma; meanwhile, impaired cognitive functions have been brought to the forefront with the offending organ, the radiosensitive hippocampus. This study aimed to assess the feasibility of hippocampus-sparing volumetric-modulated arc therapy (HS VMAT) in patients with World Health Organization (WHO) grade II glioma.Methods: HS VMAT plans and non-hippocampus-sparing volumetric-modulated arc therapy (NHS VMAT) plans were generated using a computed tomography (CT) dataset of 10 patients who underwent postoperative radiotherapy. The dose volume histogram (DVH), homogeneity index (HI), conformity index (CI), and irradiated dose of the hippocampus and other organs at risk (OARs) were analyzed.Results: No significant differences were observed in HI and CI between the two plans. Regarding the protection of OARs, HS VMAT plans were equally capable and even lowered the radiation dosages to the brainstem (35.56 vs. 41.74 Gy, p = 0.017) and spinal cord (1.34 vs. 1.43 Gy, p = 0.006). Notably, HS VMAT plans markedly decreased doses to the ipsilateral hippocampus and the contralateral hippocampus, demonstrating its efficacy in hippocampal dose reduction.Conclusion: The HS VMAT plan can be used to efficiently lower the dosage delivered to the hippocampus and may, to some extent, help lessen the risk of cognitive damage. The encouraging results of our study need to be further validated by clinical trials to confirm the benefits of the HS VMAT plans in preserving cognitive functions in patients with glioma.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1445558"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788287/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2024.1445558","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Radiotherapy can improve the survival rates of patients with glioma; meanwhile, impaired cognitive functions have been brought to the forefront with the offending organ, the radiosensitive hippocampus. This study aimed to assess the feasibility of hippocampus-sparing volumetric-modulated arc therapy (HS VMAT) in patients with World Health Organization (WHO) grade II glioma.

Methods: HS VMAT plans and non-hippocampus-sparing volumetric-modulated arc therapy (NHS VMAT) plans were generated using a computed tomography (CT) dataset of 10 patients who underwent postoperative radiotherapy. The dose volume histogram (DVH), homogeneity index (HI), conformity index (CI), and irradiated dose of the hippocampus and other organs at risk (OARs) were analyzed.

Results: No significant differences were observed in HI and CI between the two plans. Regarding the protection of OARs, HS VMAT plans were equally capable and even lowered the radiation dosages to the brainstem (35.56 vs. 41.74 Gy, p = 0.017) and spinal cord (1.34 vs. 1.43 Gy, p = 0.006). Notably, HS VMAT plans markedly decreased doses to the ipsilateral hippocampus and the contralateral hippocampus, demonstrating its efficacy in hippocampal dose reduction.

Conclusion: The HS VMAT plan can be used to efficiently lower the dosage delivered to the hippocampus and may, to some extent, help lessen the risk of cognitive damage. The encouraging results of our study need to be further validated by clinical trials to confirm the benefits of the HS VMAT plans in preserving cognitive functions in patients with glioma.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

6.20

自引率

10.60%

发文量

6641

审稿时长

14 weeks

期刊介绍： Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.